Cerus Corporation (CERS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cerus Corporation stock (CERS) is currently trading at $1.77. Cerus Corporation PS ratio (Price-to-Sales) is 1.60. Analyst consensus price target for CERS is $5.00. WallStSmart rates CERS as Sell.
- CERS PE ratio analysis and historical PE chart
- CERS PS ratio (Price-to-Sales) history and trend
- CERS intrinsic value — DCF, Graham Number, EPV models
- CERS stock price prediction 2025 2026 2027 2028 2029 2030
- CERS fair value vs current price
- CERS insider transactions and insider buying
- Is CERS undervalued or overvalued?
- Cerus Corporation financial analysis — revenue, earnings, cash flow
- CERS Piotroski F-Score and Altman Z-Score
- CERS analyst price target and Smart Rating
Cerus Corporation
📊 No data available
Try selecting a different time range
Smart Analysis
Cerus Corporation (CERS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Cerus Corporation (CERS) Key Strengths (2)
74.69% of shares held by major funds and institutions
Paying $1.60 for every $1 of annual revenue
Supporting Valuation Data
Cerus Corporation (CERS) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 5.2x book value
Small-cap company with higher risk but more growth potential
Solid revenue growth at 13.70% per year
Cerus Corporation (CERS) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales. Valuation metrics including Price/Sales (1.60) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (5.15) suggest expensive pricing. Growth concerns include Revenue Growth at 13.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -25.70%, Operating Margin at -1.11%, Profit Margin at -7.58%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -25.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 13.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CERS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CERS's Price-to-Sales ratio of 1.60x trades at a deep discount to its historical average of 30.75x (1th percentile). The current valuation is 99% below its historical high of 112.63x set in Jan 2006, and 2% above its historical low of 1.57x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~2.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cerus Corporation (CERS) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Cerus Corporation is in a turnaround phase, with management focused on restoring profitability. Revenue reached 206M with 14% growth year-over-year. The company is currently unprofitable, posting a -7.6% profit margin.
Key Findings
Generating 5M in free cash flow and 6M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -7.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.53, so expect amplified moves relative to the broader market.
Debt management: total debt of 98M is significantly higher than cash (16M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Cerus Corporation.
Bottom Line
Cerus Corporation is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(23 last 3 months)
| Insider | Type | Shares |
|---|---|---|
BENJAMIN, RICHARD J Chief Medical Officer | Sell | -40,426 |
Data sourced from SEC Form 4 filings
Last updated: 10:09:17 AM
About Cerus Corporation(CERS)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.